Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ryan J Hansen

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
American Journal of Veterinary Research|December 29, 2015
Pharmacokinetics of orally administered low-dose rapamycin in healthy dogsJeanne C Larson, Sara D Allstadt, Timothy M Fan, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 31, 2016
In Vivo and In Vitro Characterization of Basal Insulin Peglispro: A Novel Insulin AnalogRebecca A Owens, Ryan J Hansen, Steven D Kahl, et al.
Integrative Cancer Therapies|June 13, 2013
A phase I dose-finding study of silybin phosphatidylcholine (milk thistle) in patients with advanced hepatocellular carcinomaAbby B Siegel, Rupa Narayan, Rosa Rodriguez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2010
Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumorsJennifer R Diamond, Bruno R Bastos, Ryan J Hansen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 31, 2019
Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLCTriparna Sen, Carminia M Della Corte, Snezana Milutinovic, et al.
Iscience|July 18, 2024
CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and <i>CCNE1</i> amplified ovarian cancerHaineng Xu, Sarah B Gitto, Gwo-Yaw Ho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2013
Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancerAnna Spreafico, John J Tentler, Todd M Pitts, et al.
British Journal of Pharmacology|February 13, 2023
Development of a long-acting relaxin analogue, LY3540378, for treatment of chronic heart failurePetra Verdino, Stacey L Lee, Fariba N Cooper, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
American Journal of Veterinary Research|December 29, 2015
Pharmacokinetics of orally administered low-dose rapamycin in healthy dogsJeanne C Larson, Sara D Allstadt, Timothy M Fan, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 31, 2016
In Vivo and In Vitro Characterization of Basal Insulin Peglispro: A Novel Insulin AnalogRebecca A Owens, Ryan J Hansen, Steven D Kahl, et al.
Integrative Cancer Therapies|June 13, 2013
A phase I dose-finding study of silybin phosphatidylcholine (milk thistle) in patients with advanced hepatocellular carcinomaAbby B Siegel, Rupa Narayan, Rosa Rodriguez, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 7, 2010
Phase I safety, pharmacokinetic, and pharmacodynamic study of ENMD-2076, a novel angiogenic and Aurora kinase inhibitor, in patients with advanced solid tumorsJennifer R Diamond, Bruno R Bastos, Ryan J Hansen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 31, 2019
Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLCTriparna Sen, Carminia M Della Corte, Snezana Milutinovic, et al.
Iscience|July 18, 2024
CHK1 inhibitor SRA737 is active in PARP inhibitor resistant and <i>CCNE1</i> amplified ovarian cancerHaineng Xu, Sarah B Gitto, Gwo-Yaw Ho, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 13, 2013
Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancerAnna Spreafico, John J Tentler, Todd M Pitts, et al.
British Journal of Pharmacology|February 13, 2023
Development of a long-acting relaxin analogue, LY3540378, for treatment of chronic heart failurePetra Verdino, Stacey L Lee, Fariba N Cooper, et al.
Pageof 5